NGNE

Neurogene is a clinical-stage gene-therapy company with zero product revenue (FY2025 revenue $0.00, after a token $925K in FY2024) and a widening loss — net income of -$90.4M (YoY -20.2%) on operating income of -$103M, driven by R&D up 23.1% to $75.0M as the registrational Embolden trial ramps. There is no P/E or P/S to anchor to; at $35.34 on 15.6M shares the ~$551M market cap is a pure option on NGN-401 for Rett syndrome. The balance sheet is clean but shrinking: $265M equity, only $23.7M total liabilities (0.09x liabilities/equity), and $104M cash — down 24.0% YoY against a -$77.2M operating cash burn. That is roughly a year-plus of runway, and management explicitly flags in Risk Factors that it 'will require substantial additional capital' and could be 'forced to delay, reduce or eliminate clinical trials' — dilution is a when, not an if (shares already +4.3% YoY).

What keeps this a hold rather than an avoid is the clinical signal. The MD&A reports the Embolden registrational trial has enrolled 100% of participants with >50% dosed and dosing expected to complete in Q2 2026, and November 2025 interim Phase 1/2 data showed all pediatric participants gaining function (35 aggregate developmental milestones), durable prior responses, and 4 of 5 participants with ≥12 months follow-up meeting the planned Month-12 primary-endpoint responder definition. For a devastating disease with high unmet need, that is a differentiated, de-risking readout — not the 'unknowable risk' that would mandate avoid.